Storch A - Search Results

1

Functional monoamine oxidase B gene intron 13 polymorphism predicts putaminal dopamine turnover in de novo Parkinson's disease.

Löhle M, Mangone G, Wolz M, Beuthien-Baumann B, Oehme L, van den Hoff J, Kotzerke J, Reichmann H, Corvol JC, Storch A. Löhle M, et al. Among authors: storch a. Mov Disord. 2018 Sep;33(9):1496-1501. doi: 10.1002/mds.27466. Epub 2018 Sep 14. Mov Disord. 2018. PMID: 30216543

2

Neurotoxic mechanisms of 2,9-dimethyl-beta-carbolinium ion in primary dopaminergic culture.

Hamann J, Rommelspacher H, Storch A, Reichmann H, Gille G. Hamann J, et al. Among authors: storch a. J Neurochem. 2006 Aug;98(4):1185-99. doi: 10.1111/j.1471-4159.2006.03940.x. Epub 2006 Jun 19. J Neurochem. 2006. PMID: 16787411 Free article.

3

Valvular heart disease in Parkinson's disease patients treated with dopamine agonists: a reader-blinded monocenter echocardiography study.

Junghanns S, Fuhrmann JT, Simonis G, Oelwein C, Koch R, Strasser RH, Reichmann H, Storch A. Junghanns S, et al. Among authors: storch a. Mov Disord. 2007 Jan 15;22(2):234-8. doi: 10.1002/mds.21225. Mov Disord. 2007. PMID: 17094087 Clinical Trial.

4

[Gene expression profiling of classic mitochondrial disorders. Its value in finding therapeutic strategies].

Mende S, Storch A, Reichmann H. Mende S, et al. Among authors: storch a. Nervenarzt. 2007 Oct;78(10):1155-9. doi: 10.1007/s00115-007-2266-4. Nervenarzt. 2007. PMID: 17458528 Review. German.

5

Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease.

Storch A, Jost WH, Vieregge P, Spiegel J, Greulich W, Durner J, Müller T, Kupsch A, Henningsen H, Oertel WH, Fuchs G, Kuhn W, Niklowitz P, Koch R, Herting B, Reichmann H; German Coenzyme Q(10) Study Group. Storch A, et al. Arch Neurol. 2007 Jul;64(7):938-44. doi: 10.1001/archneur.64.7.nct60005. Epub 2007 May 14. Arch Neurol. 2007. PMID: 17502459 Clinical Trial.

6

Potassium channel blocker 4-aminopyridine is effective in interictal cerebellar symptoms in episodic ataxia type 2--a video case report.

Löhle M, Schrempf W, Wolz M, Reichmann H, Storch A. Löhle M, et al. Among authors: storch a. Mov Disord. 2008 Jul 15;23(9):1314-6. doi: 10.1002/mds.22071. Mov Disord. 2008. PMID: 18442126

7

Dystonia associated with hyperintense basal ganglia lesions on T1-weighted brain MRI.

Wolz M, Junghanns S, Löhle M, von Kummer R, Storch A. Wolz M, et al. Among authors: storch a. Mov Disord. 2008 Aug 15;23(11):1618-9. doi: 10.1002/mds.22128. Mov Disord. 2008. PMID: 18581474 No abstract available.

8

Orally disintegrating selegiline for the treatment of Parkinson's disease.

Löhle M, Storch A. Löhle M, et al. Among authors: storch a. Expert Opin Pharmacother. 2008 Nov;9(16):2881-91. doi: 10.1517/14656566.9.16.2881. Expert Opin Pharmacother. 2008. PMID: 18937619

9

Adherence to antiparkinson medication in a multicenter European study.

Grosset D, Antonini A, Canesi M, Pezzoli G, Lees A, Shaw K, Cubo E, Martinez-Martin P, Rascol O, Negre-Pages L, Senard A, Schwarz J, Strecker K, Reichmann H, Storch A, Löhle M, Stocchi F, Grosset K. Grosset D, et al. Among authors: storch a. Mov Disord. 2009 Apr 30;24(6):826-32. doi: 10.1002/mds.22112. Mov Disord. 2009. PMID: 19191340

10

Chocolate consumption is increased in Parkinson's disease. Results from a self-questionnaire study.

Wolz M, Kaminsky A, Löhle M, Koch R, Storch A, Reichmann H. Wolz M, et al. Among authors: storch a. J Neurol. 2009 Mar;256(3):488-92. doi: 10.1007/s00415-009-0118-9. Epub 2009 Mar 13. J Neurol. 2009. PMID: 19277767

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

417 results

Search Page

Filters